Karen Legler
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer.
Journal: Genome medicine
Published: April 11, 2025
Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer.
Journal: Journal of cancer research and clinical oncology
Published: July 29, 2023
Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis.
Journal: Frontiers in oncology
Published: December 22, 2022
The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients.
Journal: Cancer cell international
Published: December 15, 2022
Insights into the Steps of Breast Cancer-Brain Metastases Development: Tumor Cell Interactions with the Blood-Brain Barrier.
Journal: International journal of molecular sciences
Published: January 18, 2022
Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer.
Journal: Molecular oncology
Published: November 27, 2020
Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
Journal: British journal of cancer
Published: February 28, 2019
Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.
Journal: Disease markers
Published: April 09, 2018
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Journal: Cell death & disease
Published: October 19, 2017
Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
Journal: British journal of cancer
Published: September 25, 2017
Last Updated: 09/26/2026